key: cord-0831222-7nkoc12y
authors: Abboud, Hesham; Serra, Alessandro
title: The pressing questions in multiple sclerosis Care in the era of COVID-19
date: 2020-06-23
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.117005
sha: 9bf18ee448fad29d209633003d45f59379debb11
doc_id: 831222
cord_uid: 7nkoc12y

• MS patients should continue their disease modifying therapy during the pandemic. • Newly diagnosed patients should start disease modifying therapy without delay. • The effect on COVID-19 infection and future vaccination should be considered. • Agents that cause prolonged non-selective lymphopenia are not preferred. • Only severe relapses should be treated preferably with oral steroids at home.

The rapidly evolving pandemic of the severe acute respiratory syndrome corona virus type-2 (SARS-CoV-2) commonly referred to as COVID-19 has raised many questions in the neuroimmunology clinic. The implications on MS patients are complex and multifaceted. Patients and providers share similar concerns and are challenged by this unprecedented situation. The Centers for Disease Control and Prevention (CDC) designated immunocompromised patients and those with disabilities as possible COVID-19 high-risk groups. 1 The MS International Federation (MSIF) published a global advice addressing measures to reduce infection risk and implications related to disease modifying therapy (DMT) that were endorsed by the National MS Society (NMSS). Despite these efforts, many questions remain unanswered and MS clinicians are pressured to make critical decisions without clear guidance. In this viewpoint, we will evaluate some of the common questions raised by patients and colleagues. We propose recommendations that balance infection-related risks versus the risk of neurological morbidity.

Some clinicians suggested closing MS clinics to reduce exposure risk and protect immunocompromised patients. This would obviously be problematic to patients who receive their infused DMTs in the MS clinic/center and for those who require baclofen pump or botulinum toxin therapies for severe spasticity. In addition, new MS cases will continue to emerge during the pandemic and will require specialized management at MS clinics/centers. However, it is important to reduce in-person visits especially for routine follow-ups and for high-risk patients with advanced age, cardiopulmonary disease, and/or severe lymphopenia. Routine laboratory and MRI monitoring could be postponed in patients with longstanding stable disease to minimize exposure risk. 

One important question is whether we should delay DMT initiation in newly diagnosed patients until the pandemic is ameliorated. One supportive argument is the fact that relapses are usually mild and infrequent. Therefore, the benefits of delaying immunotherapy during the pandemic for a few months possibly outweigh the risk of a second relapse that may or may not occur in the following year. The counter argument is that early DMT initiation may not only help reduce relapses but also help reduce subclinical disease activity and new lesion formation, which can possibly slow disability progression and conversion to secondary progressive MS. 4 Therefore, it is essential to initiate DMT as early as possible even during the pandemic as emphasized by the MSIF and NMSS. However, several factors should be considered when selecting the new DMT including its mechanism of action, idiosyncratic effects on the immune system, associated infection risk, and its potential 

Since corticosteroids suppress T-cells, they can potentially increase SARS-CoV-2 infection-related risks, and their use is generally not advisable in COVID-19 patients. 9 Corticosteroids can shorten MS relapse duration but they do not typically change the final outcome except for optic neuritis.

Therefore, it is perhaps reasonable to avoid treating mild MS relapses during the pandemic. More importantly, it is imperative to differentiate true relapses from pseudorelapses that can be triggered by viral or other infections, and avoid the inappropriate corticosteroid administration in these

The role of infections in multiple sclerosis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Triple combination of interferon beta -1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

A potential role for integrins in host cell entry by SARS-CoV-2

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected World Health Organization

clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected

Triaging Patients with Multiple Sclerosis in the Emergency Department: Room for Improvement

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19